<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>biosimilar market on FinanClub</title>
    <link>https://finan.club/tags/biosimilar-market/</link>
    <description>Recent content in biosimilar market on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Sun, 27 Aug 2023 10:26:16 +0000</lastBuildDate><atom:link href="https://finan.club/tags/biosimilar-market/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>CVS</title>
      <link>https://finan.club/us/cvs/</link>
      <pubDate>Sun, 27 Aug 2023 10:26:16 +0000</pubDate>
      
      <guid>https://finan.club/us/cvs/</guid>
      <description>score:5
Chances: CVS launches Cordavis to target the biosimilar market. CVS Health&amp;rsquo;s efforts to market and co-produce biosimilar medicines. CVS stock potential rebound after recent drop. Positive growth potential in biosimilars sector. Investor opportunity after market cap drop. Risks: CVS Health&amp;rsquo;s Q2 earnings crashed 37%.</description>
    </item>
    
  </channel>
</rss>
